NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Azithromycin for COVID-19 Treatment in Outpatients Nationwide

TerminatedPhase 3

Sponsor: Thomas M. Lietman

Conditions: COVID-19, SARS-CoV-2

Interventions: Azithromycin, Placebos

Countries: United States

This individually randomized telemedicine-based trial aims to evaluate the efficacy of a single dose of azithromycin for prevention of progression of COVID-19 in patients with a recent positive SARS-CoV-2 test who are not currently hospitalized.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Evidence of a positive SARS-CoV-2 test and test results received within the previous seven days
* Not currently hospitalized
* Willing and able to receive study drug by mail
* Willing and able to do the study questionnaires at baseline, day 3, 7, 14, 21 days via email or over the phone
* No known allergy or other contraindication to macrolides
* Age 18 years or older at the time of enrollment
* No known history of prolongation of the QT interval (eg. History of torsades de pointes, congenital long QT syndrome, bradyarrhthmia)
* No recent use of hydroxychloroquine within the past 7 days for participants \>55 years of age
* Not currently taking nelfinavir or warfarin (Coumadin)
* Provision of informed consent
* Not currently pregnant

Locations (1)

San Francisco, California, United States